SAN DIEGO, Dec. 7, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the Oppenheimer Annual Healthcare Conference in New York. The presentation is scheduled for Tuesday, December 13 at 1:00 p.m. EST (10:00 a.m. PST). To listen to the live webcast or a replay of the presentation, please visit the Investor section of the Company’s Web site at www.halozyme.com. A replay will be available for 90 days after the event.
(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. The Company’s product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s ENHANZE Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition to partnerships that use Halozyme’s ENHANZE Technology, the Company has a number of product candidates in its pipeline that target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
Halozyme Contact
Kurt Gustafson
Chief Financial Officer
(858) 704-8272
kgustafson@halozyme.com
SOURCE Halozyme Therapeutics, Inc.
